Cardiac Resynchronisation Therapy in Patients with Moderate to Severe Heart Failure in Germany: A Cost-Utility Analysis of the Additional Defibrillator
Open Access
- 25 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Applied Health Economics and Health Policy
- Vol. 19 (1), 57-68
- https://doi.org/10.1007/s40258-020-00571-y
Abstract
Background Cardiac resynchronisation therapy (CRT) is a well-established form of treatment for patients with heart failure and cardiac dyssynchrony. There are two different types of CRT devices: the biventricular pacemaker (CRT-P) and the biventricular defibrillator (CRT-D). The latter is more complex but also more expensive. For the majority of patients who are eligible for CRT, both devices are appropriate according to current guidelines. The purpose of this study was to conduct a cost-utility analysis for CRT-D compared to CRT-P from a German payer’s perspective. Methods A cohort Markov-model was developed to assess average costs and quality-adjusted life-years (QALY) for CRT-D and CRT-P. The model consisted of six stages: one for the device implementation, one for the absorbing state death, and two stages (“Stable” and “Hospital”) for either a CRT device or medical therapy. The time horizon was 20 years. Deterministic and probabilistic sensitivity analyses and scenario analyses were conducted. Results The incremental cost-effectiveness ratio (ICER) of CRT-D compared with CRT-P was €24,659 per additional QALY gained. In deterministic sensitivity analysis, the survival advantage of CRT-D to CRT-P was the most influential input parameter. In the probabilistic sensitivity analysis 96% of the simulated cases were more effective but also more costly. Conclusions Therapy with CRT-D compared to CRT-P resulted in an additional gain of QALYs, but was more expensive. In addition, the ICER was subject to uncertainty, especially due to the uncertainty in the survival benefit. A randomised controlled trial and subgroup analyses would be desirable to further inform decision making.Keywords
Funding Information
- Innovationsfonds (01VSF17050)
This publication has 53 references indexed in Scilit:
- Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: The perspective of a middle-income country's public health systemInternational Journal of Cardiology, 2013
- Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curvesBMC Medical Research Methodology, 2012
- Resource use and costs in systolic heart failure according to disease severity: a pooled analysis from the German Competence Network Heart FailureJournal of Public Health, 2011
- Posttraumatic Stress and the Implantable Cardioverter-Defibrillator PatientCirculation: Arrhythmia and Electrophysiology, 2011
- Cardiac-Resynchronization Therapy for Mild-to-Moderate Heart FailureThe New England Journal of Medicine, 2010
- Utility Estimates for Decision–Analytic Modeling in Chronic Heart Failure—Health States Based on New York Heart Association Classes and Number of RehospitalizationsValue in Health, 2009
- Prognostic Importance of Defibrillator Shocks in Patients with Heart FailureThe New England Journal of Medicine, 2008
- Clinical epidemiology of heart failureHeart, 2007
- The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillatorEuropean Heart Journal, 2006
- Cardiac Resynchronization Therapy (CRT) in Heart Failure—A Model to Assess the Economic Value of this New Medical TechnologyValue in Health, 2005